{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:23:40Z","timestamp":1780349020167,"version":"3.54.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.cpet.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T03:36:55Z","timestamp":1525664215000},"page":"395-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of Fludeoxyglucose in Breast Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"David","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2018.02.003_bib1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2000.18.8.1676","article-title":"Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy","volume":"18","author":"Smith","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2000.18.8.1689","article-title":"Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer","volume":"18","author":"Schelling","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib3","first-page":"1806","article-title":"Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy","volume":"44","author":"Mankoff","year":"2003","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib4","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.05.7406","article-title":"Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography","volume":"24","author":"Rousseau","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-007-0459-5","article-title":"[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy","volume":"34","author":"Berriolo-Riedinger","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-006-9316-7","article-title":"Monitoring primary breast cancer throughout chemotherapy using FDG-PET","volume":"102","author":"McDermott","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.02.003_bib7","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1200\/JCO.2007.15.4385","article-title":"Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer","volume":"26","author":"Dunnwald","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","article-title":"Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose","volume":"27","author":"Schwarz-Dose","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00330-009-1303-z","article-title":"The role of 18F-FDG PET\/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer","volume":"19","author":"Kumar","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2018.02.003_bib10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00259-009-1116-y","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"36","author":"Duch","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib11","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr2591","article-title":"The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET","volume":"12","author":"Schneider-Kolsky","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-011-1780-z","article-title":"Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis","volume":"131","author":"Wang","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.02.003_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3816\/CBC.2000.n.014","article-title":"Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients","volume":"1","author":"Gennari","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1076-6332(03)80461-0","article-title":"Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy","volume":"9","author":"Stafford","year":"2002","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cpet.2018.02.003_bib15","first-page":"1144","article-title":"Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET","volume":"46","author":"Dose Schwarz","year":"2005","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib16","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-06-0383","article-title":"Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer","volume":"12","author":"Couturier","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9435-1","article-title":"Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)","volume":"105","author":"Specht","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.02.003_bib18","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2007.11.2854","article-title":"Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography\/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer","volume":"25","author":"Du","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","article-title":"Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT","volume":"247","author":"Tateishi","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2018.02.003_bib20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.clon.2010.05.021","article-title":"Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients","volume":"22","author":"Huyge","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.cpet.2018.02.003_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00259-011-1981-z","article-title":"Assessment of response to endocrine therapy using FDG PET\/CT in metastatic breast cancer: a pilot study","volume":"39","author":"Mortazavi-Jehanno","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib23","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2014.60.0353","volume":"33","author":"Lin","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib24","doi-asserted-by":"crossref","first-page":"e3753","DOI":"10.1097\/MD.0000000000003753","article-title":"Effectiveness of 18F-FDG-PET\/CT vs bone scintigraphy in treatment response assessment of bone metastases in breast cancer","volume":"95","author":"Al-Muqbel","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cpet.2018.02.003_bib25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2967\/jnumed.115.166629","article-title":"The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET\/CT using PERCIST","volume":"57","author":"Pinker","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib26","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X","article-title":"Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study","volume":"72","author":"Brown","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","article-title":"Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib28","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","article-title":"Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations","volume":"18","author":"Avril","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/bjs.6459","article-title":"Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer","volume":"96","author":"Gil-Rendo","year":"2009","journal-title":"Br J Surg"},{"key":"10.1016\/j.cpet.2018.02.003_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":"Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur","volume":"38","author":"Groheux","year":"2011","journal-title":"J\u00a0Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23226","volume":"112","author":"Basu","year":"2008","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2018.02.003_bib32","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-8140(03)00270-6","article-title":"Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms","volume":"69","author":"Daisne","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib34","doi-asserted-by":"crossref","first-page":"e94017","DOI":"10.1371\/journal.pone.0094017","article-title":"Relationship between tumor heterogeneity measured on FDG-PET\/CT and pathological prognostic factors in invasive breast cancer","volume":"9","author":"Soussan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2018.02.003_bib35","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-015-3110-x","article-title":"Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET\/CT volumetric and heterogeneity features in stage II\/III breast cancer? Eur","volume":"42","author":"Groheux","year":"2015","journal-title":"J\u00a0Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13058-016-0793-2","article-title":"(18)FDG-PET\/CT for predicting the outcome in ER+\/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis","volume":"19","author":"Groheux","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2967\/jnumed.110.077461","article-title":"Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs","volume":"52","author":"Stahl","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib38","first-page":"1044","article-title":"SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences","volume":"44","author":"Beaulieu","year":"2003","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib39","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib43","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","article-title":"EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies","volume":"44","author":"Aide","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib45","unstructured":"NCCN clinical practice guidelines in oncology. Breast cancer. Version 4. 2017. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed March 03, 2018."},{"key":"10.1016\/j.cpet.2018.02.003_bib46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2007.15.3510","article-title":"Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease","volume":"26","author":"Gralow","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib47","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S1470-2045(14)71020-4","article-title":"Predicting pathological complete response in breast cancer early","volume":"15","author":"Groheux","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(15)60017-4","article-title":"Pathological complete response in breast cancer","volume":"385","author":"Hindi\u00e9","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2018.02.003_bib49","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib50","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/1078-0432.CCR-13-0916","article-title":"Neoadjuvant therapy as a platform for drug development and approval in breast cancer","volume":"19","author":"Bardia","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib51","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1258\/ar.2012.110603","article-title":"18F-FDG PET\/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis","volume":"53","author":"Cheng","year":"2012","journal-title":"Acta Radiol"},{"key":"10.1016\/j.cpet.2018.02.003_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clbc.2013.02.003","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis","volume":"13","author":"Mghanga","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"10.1016\/j.cpet.2018.02.003_bib53","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1007\/s00330-017-4831-y","article-title":"The accuracy of (18)F-FDG PET\/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review","volume":"27","author":"Tian","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cpet.2018.02.003_bib54","doi-asserted-by":"crossref","first-page":"3746232","DOI":"10.1155\/2016\/1235429","article-title":"The role of (18)F-FDG PET\/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis","volume":"2016","author":"Liu","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cpet.2018.02.003_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1148\/radiol.12111177","article-title":"Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET\/CT and dynamic contrast-enhanced MR Imaging\u2013prospective assessment","volume":"263","author":"Tateishi","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2018.02.003_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2967\/jnumed.112.108837","article-title":"Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"54","author":"Hatt","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.115.163907","article-title":"18F-FDG PET\/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: influence of the chemotherapy regimen","volume":"57","author":"Groheux","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-015-3295-z","article-title":"(18)F-FDG PET\/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials","volume":"43","author":"Groheux","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib59","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/1078-0432.CCR-10-0026","article-title":"Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer","volume":"16","author":"Specht","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib60","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1093\/annonc\/mds071","article-title":"Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes","volume":"23","author":"Humbert","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1148\/radiol.2015141638","article-title":"Early metabolic response to neoadjuvant treatment: FDG PET\/CT criteria according to breast cancer subtype","volume":"277","author":"Groheux","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2018.02.003_bib62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00259-010-1660-5","article-title":"Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET\/CT: defining a clinical aim. Eur","volume":"38","author":"Groheux","year":"2011","journal-title":"J\u00a0Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib63","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib64","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2018.02.003_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2967\/jnumed.111.094045","article-title":"Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse","volume":"53","author":"Groheux","year":"2012","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib67","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2012.12.024","article-title":"Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy","volume":"49","author":"Zucchini","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib68","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","article-title":"FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer","volume":"22","author":"Koolen","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.cpet.2018.02.003_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00259-013-2515-7","article-title":"Sequential (18)F-FDG PET\/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy","volume":"41","author":"Koolen","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib70","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ejca.2014.04.020","article-title":"Early assessment with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer","volume":"50","author":"Groheux","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2967\/jnumed.114.144741","article-title":"TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer","volume":"56","author":"Connolly","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib72","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1158\/1078-0432.CCR-15-0384","article-title":"Identification of biomarkers including 18FDG-PET\/CT for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer","volume":"21","author":"Humbert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib73","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2967\/jnumed.116.172759","article-title":"18F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer","volume":"57","author":"Humbert","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib74","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2018.02.003_bib75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/cncr.24820","article-title":"Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy","volume":"116","author":"Martoni","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib77","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2013.469","article-title":"HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment","volume":"109","author":"Groheux","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib78","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"Gebhart","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib79","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00259-014-2739-1","article-title":"HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy","volume":"41","author":"Humbert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib80","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"Coudert","year":"2014","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.cpet.2018.02.003_bib81","doi-asserted-by":"crossref","first-page":"29388","DOI":"10.18632\/oncotarget.5001","article-title":"18F-fluorodeoxyglucose (FDG) PET\/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer","volume":"6","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpet.2018.02.003_bib82","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/cncr.28020","article-title":"Estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography during neoadjuvant chemotherapy","volume":"119","author":"Groheux","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib83","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2967\/jnumed.115.154138","article-title":"Baseline tumor 18F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+\/HER2- breast cancer","volume":"56","author":"Groheux","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib84","doi-asserted-by":"crossref","first-page":"e105905","DOI":"10.1371\/journal.pone.0105905","article-title":"[18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer","volume":"9","author":"Ahn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2018.02.003_bib85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-015-3303-9","article-title":"Utility of (18)F FDG-PET\/CT for predicting prognosis of luminal-type breast cancer","volume":"150","author":"Aogi","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.02.003_bib86","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00259-013-2616-3","article-title":"Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer","volume":"41","author":"Humbert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2967\/jnumed.106.037382","article-title":"Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF","volume":"48","author":"Doot","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib88","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cpet.2018.02.003_bib89","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.12110853","article-title":"Performance of FDG PET\/CT in the clinical management of breast cancer","volume":"266","author":"Groheux","year":"2013","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.cpet.2018.02.003_bib90","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","article-title":"Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer","volume":"44","author":"Riedl","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib91","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.02.003_bib92","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","article-title":"Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer","volume":"32","author":"Nakai","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.02.003_bib93","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rcl.2007.05.007","article-title":"Detection of bone metastases in breast cancer by positron emission tomography","volume":"45","author":"Schirrmeister","year":"2007","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.cpet.2018.02.003_bib94","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2009.27.5743","article-title":"Integrated positron emission tomography\/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer","volume":"28","author":"Morris","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib95","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/djs451","article-title":"Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer","volume":"104","author":"Groheux","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cpet.2018.02.003_bib96","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2005.11.024","article-title":"FDG-PET and beyond: molecular breast cancer imaging","volume":"23","author":"Quon","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib97","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2001.19.11.2797","article-title":"Metabolic flare: indicator of hormone responsiveness in advanced breast cancer","volume":"19","author":"Mortimer","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-008-9953-0","article-title":"PET-based\u00a0estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer","volume":"113","author":"Dehdashti","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.02.003_bib99","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1002\/cncr.27579","article-title":"Standardized uptake value by positron emission tomography\/computed tomography as a prognostic variable in metastatic breast cancer","volume":"118","author":"Morris","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.02.003_bib100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/cam4.119","article-title":"Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer","volume":"2","author":"Ulaner","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpet.2018.02.003_bib101","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2005.04.6326","article-title":"Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy","volume":"24","author":"Cachin","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.02.003_bib102","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","article-title":"Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype","volume":"29","author":"Loo","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859818300245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859818300245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T16:50:45Z","timestamp":1604249445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859818300245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1556859818300245"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2018.02.003","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Fludeoxyglucose in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}